Marisa Wexler, MS, senior science writer —

Measuring blood levels of three molecules — SAM, guanine, and NT-proBNP — could help identify pulmonary arterial hypertension (PAH) in children with congenital heart diseases (CHD), a study suggests. “This 3-marker panel has the potential to be used in clinical practice for the early diagnosis and screening of PAH-CHD,”…

A noninvasive measure of heart and blood vessel function called the TAPSE/PASP ratio could help prioritize people with pulmonary arterial hypertension (PAH) who may benefit most from a lung transplant, according to a new study. “We demonstrated that the echocardiographic index of TAPSE/PASP … was lower in patients who…

Treatment with Pulnovo Medical’s pulmonary artery denervation (PADN) device significantly reduced the risk of clinical worsening among people with pulmonary arterial hypertension (PAH) in a clinical trial, according to new data announced by the company. Chen Shaoliang, a professor at Nanjing First Hospital of Nanjing Medical University in China,…

The experimental therapy levosimendan has been awarded a U.S. patent covering its use for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to developer Tenax Therapeutics. The United States Patent and Trademark Office (USPTO) issued a notice of allowance to Tenax for a patent for…

Treatment with phosphodiesterase-5 (PDE5) inhibitors can improve blood flow parameters and exercise capacity in people with pulmonary hypertension (PH), according to a new analysis of clinical trial data. “The study found that the reduction in mean PAP [peripheral arterial pressure] was significantly greater in patients receiving PDE5 inhibitors,” the…

The U.S. Food and Drug Administration (FDA) has approved the third generation of Genosyl, Vero Biotech‘s tankless system for nitric oxide delivery, for use as part of care for newborns with pulmonary hypertension. “The continuous innovation of the GENOSYL Delivery System represents our commitment to neonatal intensive care…

Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments in research, care, and treatment related to pulmonary hypertension (PH). We hope to continue to be a resource for the PH community in the coming year. Here is a…

Merck’s investigational inhaled treatment MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a Phase 1 clinical trial. Results showed that the therapy improved blood flow in patients’ lungs, but did not affect blood pressure elsewhere in the body. “The promising pulmonary selectivity and…

Treatment with seralutinib (GB002), an inhaled investigational therapy, significantly improved measures of blood pressure in the lungs of people with pulmonary arterial hypertension (PAH) in the Phase 2 TORREY study, meeting the trial’s main goal. Promising effects also were seen on measures of exercise capacity and heart structure, with these…

Immune cells called eosinophils help protect against the progression of pulmonary hypertension (PH) by reducing lung inflammation and regulating the growth of muscle cells around blood vessels, a new study indicates. The study, “Eosinophils Protect Against Pulmonary Hypertension through 14-HDHA and 17-HDHA,” was published in the …

Obstructive sleep apnea (OSA) is common among people with pulmonary hypertension (PH), and PH patients with OSA are more likely to report co-occurring health problems like diabetes and high blood pressure, a new study done at a center in China reports. In fact, the study found that more than…

Step count and heart rate data from wearable sensors can be of use as real-world approximations of common clinical tests of fitness, a study drawing on data from people with pulmonary arterial hypertension (PAH) shows. “Activity tracker-measured health parameters could serve as proxies for clinically measured health parameters of…